Literature DB >> 8282816

Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

P H Sorensen1, C S Chen, F O Smith, D C Arthur, P H Domer, I D Bernstein, S J Korsmeyer, G D Hammond, J H Kersey.   

Abstract

Cytogenetic studies have previously identified abnormalities of chromosome band 11q23 in many cases of infant acute leukemia. Recent studies by ourselves and others have demonstrated breakpoint clustering in acute leukemias bearing translocations involving 11q23, and a Drosophila trithorax gene homologue (called MLL, HRX, or ALL-1) has been shown to span the 11q23 breakpoints of these translocations. To determine if this gene is affected in infant acute myeloid leukemia (AML), we have analyzed 26 infant AML cases for molecular alterations of this 11q23 gene. 15 out of 26 cases studied (58%) showed rearrangement of the MLL gene at the molecular level, and these rearrangements were clustered within an approximately 11-kb region containing nine exons of this gene. Moreover, 14 of the 15 cases with 11q23 rearrangements (93%) had myelomonocytic or monocytic phenotypes (M4 or M5 FAB subtypes, respectively), both of which are associated with a poor prognosis in childhood AML. In contrast, only 1 of 11 nonrearranged cases had an M4 or M5 phenotype (P = 0.00002). Rearrangement also correlated significantly with hyperleukocytosis (P = 0.02), another clinical parameter associated with poor outcome in this disease. Our results demonstrate that molecular rearrangements of MLL are common in M4 or M5 infant AML, and suggest that alteration of this gene may result in abnormal control of proliferation and differentiation in monocytic progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282816      PMCID: PMC293805          DOI: 10.1172/JCI116978

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Mapping chromosome band 11q23 in human acute leukemia with biotinylated probes: identification of 11q23 translocation breakpoints with a yeast artificial chromosome.

Authors:  J D Rowley; M O Diaz; R Espinosa; Y D Patel; E van Melle; S Ziemin; P Taillon-Miller; P Lichter; G A Evans; J H Kersey
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Authors:  S Ziemin-van der Poel; N R McCabe; H J Gill; R Espinosa; Y Patel; A Harden; P Rubinelli; S D Smith; M M LeBeau; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance.

Authors:  F O Smith; B C Lampkin; C Versteeg; D A Flowers; P A Dinndorf; J D Buckley; W G Woods; G D Hammond; I D Bernstein
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

4.  An altered 11-kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation.

Authors:  G Cimino; T Nakamura; Y Gu; O Canaani; R Prasad; W M Crist; A J Carroll; M Baer; C D Bloomfield; P C Nowell
Journal:  Cancer Res       Date:  1992-07-01       Impact factor: 12.701

5.  T cell receptor gamma and delta rearrangements in hematologic malignancies. Relationship to lymphoid differentiation.

Authors:  F Griesinger; J M Greenberg; J H Kersey
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy.

Authors:  C M Rubin; D C Arthur; W G Woods; B J Lange; P C Nowell; J D Rowley; J Nachman; B Bostrom; E S Baum; C R Suarez
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

7.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.

Authors:  C H Pui; R C Ribeiro; M L Hancock; G K Rivera; W E Evans; S C Raimondi; D R Head; F G Behm; M H Mahmoud; J T Sandlund
Journal:  N Engl J Med       Date:  1991-12-12       Impact factor: 91.245

8.  Breakpoint clustering in t(4;11)(q21;q23) acute leukemia.

Authors:  C S Chen; P S Medberry; D C Arthur; J H Kersey
Journal:  Blood       Date:  1991-11-15       Impact factor: 22.113

9.  Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations.

Authors:  Y Akao; M Seto; T Takahashi; M Saito; K R Utsumi; S Nakazawa; R Ueda
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

10.  Cloning of ALL-1, the locus involved in leukemias with the t(4;11)(q21;q23), t(9;11)(p22;q23), and t(11;19)(q23;p13) chromosome translocations.

Authors:  G Cimino; D T Moir; O Canaani; K Williams; W M Crist; S Katzav; L Cannizzaro; B Lange; P C Nowell; C M Croce
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

View more
  21 in total

Review 1.  Dietary flavonoids and the MLL gene: A pathway to infant leukemia?

Authors:  J A Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

2.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Authors:  Jolanta Grembecka; Shihan He; Aibin Shi; Trupta Purohit; Andrew G Muntean; Roderick J Sorenson; Hollis D Showalter; Marcelo J Murai; Amalia M Belcher; Thomas Hartley; Jay L Hess; Tomasz Cierpicki
Journal:  Nat Chem Biol       Date:  2012-01-29       Impact factor: 15.040

3.  Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.

Authors:  Marcelo J Murai; Maksymilian Chruszcz; Gireesh Reddy; Jolanta Grembecka; Tomasz Cierpicki
Journal:  J Biol Chem       Date:  2011-07-13       Impact factor: 5.157

Review 4.  The role of HTS in drug discovery at the University of Michigan.

Authors:  Martha J Larsen; Scott D Larsen; Andrew Fribley; Jolanta Grembecka; Kristoff Homan; Anna Mapp; Andrew Haak; Zaneta Nikolovska-Coleska; Jeanne A Stuckey; Duxin Sun; David H Sherman
Journal:  Comb Chem High Throughput Screen       Date:  2014-03       Impact factor: 1.339

Review 5.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

6.  Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience.

Authors:  Igne Kairiene; Ramune Pasauliene; Nadezda Lipunova; Goda Vaitkeviciene; Lina Rageliene; Jelena Rascon
Journal:  Eur J Pediatr       Date:  2017-08-15       Impact factor: 3.183

7.  MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.

Authors:  Thien N Sam; John H Kersey; Amy M Linabery; Kimberly J Johnson; Nyla A Heerema; Joanne M Hilden; Stella M Davies; Gregory H Reaman; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2011-07-28       Impact factor: 3.167

8.  Pseudo-rearrangement of the MLL gene at chromosome 11q23: a cautionary note on genotype analysis of leukaemia patients.

Authors:  M Stanulla; H J Schünemann; S Thandla; M L Brecher; P D Aplan
Journal:  Mol Pathol       Date:  1998-04

9.  Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia.

Authors:  Tomasz Cierpicki; Laurie E Risner; Jolanta Grembecka; Stephen M Lukasik; Relja Popovic; Monika Omonkowska; David D Shultis; Nancy J Zeleznik-Le; John H Bushweller
Journal:  Nat Struct Mol Biol       Date:  2009-12-13       Impact factor: 15.369

10.  Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.

Authors:  Jianbo Yang; Matthew A Price; Gui Yuan Li; Menashe Bar-Eli; Ravi Salgia; Ramasamy Jagedeeswaran; Jennifer H Carlson; Soldano Ferrone; Eva A Turley; James B McCarthy
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.